GlassScriptPhysician profile
Ephraim E Temple
NPI 1679083802
$6,340.13
in general payments reported to CMS, 2019-2025
48 companies · $895 in 2025
The $895 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,765 · 2022: $1,318 · 2023: $1,157 · 2024: $1,206 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,215.12 | 2021-2025 | Farxiga, Fasenra, Breztri |
| Abbvie INC. | $786.70 | 2021-2025 | |
| Novo Nordisk INC | $721.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.78 | 2021-2025 | Jardiance |
| Daiichi Sankyo INC. | $346.89 | 2021-2025 | Injectafer |
| Pfizer INC. | $325.03 | 2021-2025 | |
| Lucid Diagnostics INC. | $264.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $224.34 | 2021-2025 | |
| Abbott Laboratories | $198.72 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $197.71 | 2021-2022 | |
| Lilly USA, LLC | $181.03 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $101.00 | 2022-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $98.75 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $93.89 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.49 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ephraim Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.